GeloMyrtol 300 mg
Natural health product licensed in Canada
- Other names
- Gelo Myrtol 300 mg, Myrtol 300 mg
- Licence holder
- G. Pohl-Boskamp GmbH & Co. KG
- NPN or DIN-HM
- 80026904
- Status
- Active licence
- Licence date
- 16 August 2011
- Revision date
- 22 April 2026
- Form
- Gélule entéro-soluble
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Citrus sinensis Source : Pelure (fruit) | 96 mg | Not calculated |
| Myrtus communis Source : Leaf and twig | 3 mg | Not calculated |
Non-medicinal ingredients
Acide citrique, ester de triéthyle, Sorbitol solution, non-crystallizing, Dextrine, Glycyrrhizinate d'ammonium, acide hydrochlorique, Talc, Hydrogenated Rapeseed oil, Gélatine, sulfate sodique de lauryle, Hypromellose acetate succinate, Glycérine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 4 Tous les jours |
| Adult (Conditions chroniques) | Not specified | 1 Capsule | 3 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Reduces risk of acute exacerbations from chronic bronchitis when used in conjunction with professionally supervised conventional treatment. Acts as a supportive therapy to help relieve sinus symptoms associated with acute sinusitis including: sinus headache, sinus pain and pressure / Acts as a supportive therapy to help relieve the acute sinus symptoms: sinus headache, sinus pain and pressure. For the temporary relief of symptoms associated with day time and night time coughing due to bronchitis. Acts as a supportive therapy to help relieve acute sinus symptoms by thinning the mucus. Promotes / facilitates / supports expectoration associated with bronchitis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80026904
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.